Successful regression of newly formed corneal neovascularization by subconjunctival injection of bevacizumab in patients with chemical burns
To investigate the effect and timing of subconjunctival bevacizumab injection on inhibiting corneal neovascularization (CorNV) in patients after chemical burns. Patients with CorNV secondary to chemical burns were involved. Two subconjunctival injections of bevacizumab (2.5 mg/0.1 mL per involved qu...
Saved in:
| Published in | Frontiers in medicine Vol. 10; p. 1210765 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Switzerland
Frontiers Media S.A
22.06.2023
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | To investigate the effect and timing of subconjunctival bevacizumab injection on inhibiting corneal neovascularization (CorNV) in patients after chemical burns.
Patients with CorNV secondary to chemical burns were involved. Two subconjunctival injections of bevacizumab (2.5 mg/0.1 mL per involved quadrant) with an interval of 4 weeks were administered, and followed up a year. The area occupied by neovascular vessels (NA), accumulative neovascular length (NL), mean neovascular diameter (ND), best-corrected visual acuity (BCVA) and intraocular pressure (IOP) were evaluated. Complication was also recorded.
Eleven patients with CorNV were involved. Eight patients had a history of surgery (four had amniotic grafts, one had keratoplasty, and three had amniotic grafts and keratoplasty). Decreasing in NA, NL, and ND were statistically significant at each time point compared to the baseline (
0.01). CorNV that developed within 1 month was considerably regressed, and vessels with fibrovascular membranes were found to be narrower and shorter than pretreatment. BCVA improved in five patients (from one to five lines), remained unchanged in five patients, and decreased in one patient compared to pretreatment.
Subconjunctival bevacizumab injection has a particular potential for the regression of CorNV, especially newly formed within 1 month in patients after chemical burns. |
|---|---|
| AbstractList | To investigate the effect and timing of subconjunctival bevacizumab injection on inhibiting corneal neovascularization (CorNV) in patients after chemical burns.PurposeTo investigate the effect and timing of subconjunctival bevacizumab injection on inhibiting corneal neovascularization (CorNV) in patients after chemical burns.Patients with CorNV secondary to chemical burns were involved. Two subconjunctival injections of bevacizumab (2.5 mg/0.1 mL per involved quadrant) with an interval of 4 weeks were administered, and followed up a year. The area occupied by neovascular vessels (NA), accumulative neovascular length (NL), mean neovascular diameter (ND), best-corrected visual acuity (BCVA) and intraocular pressure (IOP) were evaluated. Complication was also recorded.MethodsPatients with CorNV secondary to chemical burns were involved. Two subconjunctival injections of bevacizumab (2.5 mg/0.1 mL per involved quadrant) with an interval of 4 weeks were administered, and followed up a year. The area occupied by neovascular vessels (NA), accumulative neovascular length (NL), mean neovascular diameter (ND), best-corrected visual acuity (BCVA) and intraocular pressure (IOP) were evaluated. Complication was also recorded.Eleven patients with CorNV were involved. Eight patients had a history of surgery (four had amniotic grafts, one had keratoplasty, and three had amniotic grafts and keratoplasty). Decreasing in NA, NL, and ND were statistically significant at each time point compared to the baseline (p < 0.01). CorNV that developed within 1 month was considerably regressed, and vessels with fibrovascular membranes were found to be narrower and shorter than pretreatment. BCVA improved in five patients (from one to five lines), remained unchanged in five patients, and decreased in one patient compared to pretreatment.ResultsEleven patients with CorNV were involved. Eight patients had a history of surgery (four had amniotic grafts, one had keratoplasty, and three had amniotic grafts and keratoplasty). Decreasing in NA, NL, and ND were statistically significant at each time point compared to the baseline (p < 0.01). CorNV that developed within 1 month was considerably regressed, and vessels with fibrovascular membranes were found to be narrower and shorter than pretreatment. BCVA improved in five patients (from one to five lines), remained unchanged in five patients, and decreased in one patient compared to pretreatment.Subconjunctival bevacizumab injection has a particular potential for the regression of CorNV, especially newly formed within 1 month in patients after chemical burns.ConclusionSubconjunctival bevacizumab injection has a particular potential for the regression of CorNV, especially newly formed within 1 month in patients after chemical burns. To investigate the effect and timing of subconjunctival bevacizumab injection on inhibiting corneal neovascularization (CorNV) in patients after chemical burns. Patients with CorNV secondary to chemical burns were involved. Two subconjunctival injections of bevacizumab (2.5 mg/0.1 mL per involved quadrant) with an interval of 4 weeks were administered, and followed up a year. The area occupied by neovascular vessels (NA), accumulative neovascular length (NL), mean neovascular diameter (ND), best-corrected visual acuity (BCVA) and intraocular pressure (IOP) were evaluated. Complication was also recorded. Eleven patients with CorNV were involved. Eight patients had a history of surgery (four had amniotic grafts, one had keratoplasty, and three had amniotic grafts and keratoplasty). Decreasing in NA, NL, and ND were statistically significant at each time point compared to the baseline ( 0.01). CorNV that developed within 1 month was considerably regressed, and vessels with fibrovascular membranes were found to be narrower and shorter than pretreatment. BCVA improved in five patients (from one to five lines), remained unchanged in five patients, and decreased in one patient compared to pretreatment. Subconjunctival bevacizumab injection has a particular potential for the regression of CorNV, especially newly formed within 1 month in patients after chemical burns. PurposeTo investigate the effect and timing of subconjunctival bevacizumab injection on inhibiting corneal neovascularization (CorNV) in patients after chemical burns.MethodsPatients with CorNV secondary to chemical burns were involved. Two subconjunctival injections of bevacizumab (2.5 mg/0.1 mL per involved quadrant) with an interval of 4 weeks were administered, and followed up a year. The area occupied by neovascular vessels (NA), accumulative neovascular length (NL), mean neovascular diameter (ND), best-corrected visual acuity (BCVA) and intraocular pressure (IOP) were evaluated. Complication was also recorded.ResultsEleven patients with CorNV were involved. Eight patients had a history of surgery (four had amniotic grafts, one had keratoplasty, and three had amniotic grafts and keratoplasty). Decreasing in NA, NL, and ND were statistically significant at each time point compared to the baseline (p < 0.01). CorNV that developed within 1 month was considerably regressed, and vessels with fibrovascular membranes were found to be narrower and shorter than pretreatment. BCVA improved in five patients (from one to five lines), remained unchanged in five patients, and decreased in one patient compared to pretreatment.ConclusionSubconjunctival bevacizumab injection has a particular potential for the regression of CorNV, especially newly formed within 1 month in patients after chemical burns. |
| Author | He, Li-wen Peng, Wen-yan Zhou, Bin-Bing Yin, Xiao-fang Zhou, Tao Zhou, Shi-you |
| AuthorAffiliation | 3 Department of Ophthalmology, The Affiliated First Hospital of Guangdong Pharmaceutical University , Guangzhou , China 4 Department of Ophthalmology, First People’s Hospital of Guiyang , Guiyang , China 1 State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangdong Provincial Clinical Research Center for Ocular Diseases , Guangzhou , China 2 Department of Ophthalmology, The Second People's Hospital of Foshan , Foshan , China |
| AuthorAffiliation_xml | – name: 4 Department of Ophthalmology, First People’s Hospital of Guiyang , Guiyang , China – name: 2 Department of Ophthalmology, The Second People's Hospital of Foshan , Foshan , China – name: 1 State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangdong Provincial Clinical Research Center for Ocular Diseases , Guangzhou , China – name: 3 Department of Ophthalmology, The Affiliated First Hospital of Guangdong Pharmaceutical University , Guangzhou , China |
| Author_xml | – sequence: 1 givenname: Wen-yan surname: Peng fullname: Peng, Wen-yan – sequence: 2 givenname: Li-wen surname: He fullname: He, Li-wen – sequence: 3 givenname: Xiao-fang surname: Yin fullname: Yin, Xiao-fang – sequence: 4 givenname: Bin-Bing surname: Zhou fullname: Zhou, Bin-Bing – sequence: 5 givenname: Tao surname: Zhou fullname: Zhou, Tao – sequence: 6 givenname: Shi-you surname: Zhou fullname: Zhou, Shi-you |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37425330$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1Us1uEzEQtlARLaUPwAXtkUuCf9fZE0IVtJUqcQAkbpY9thNHu3awd1Olz8BD4zQpapE4eTTz_cgz32t0ElN0CL0leM7YovvgB2fnFFM2J5Rg2YoX6IzSrp0txOLnyZP6FF2UssYYE0YFJ-wVOmWSU8EYPkO_v00ArhQ_9U12y1zLkGKTfBPdXb9rfMrVp4GUo9N9baatLjD1Ood7Pe6hZteUyUCK6ynCGLYVFeLawXjUMW6rIdxPgzZ10Gwqy8WxNHdhXDWwckOASjFTjuUNeul1X9zF8T1HP758_n55Pbv9enVz-el2BrxtxxlnxDgJwJmxvPOOWG464TUWXHIiMNawoJy3mLfWWkosMVISSUC2xHju2Tm6OejapNdqk8Og804lHdRDI-Wl0nkM0DtlOBBvQRBpGXfCasY7MKIzXnOCtalaHw9am8nUTUH9W9b9M9HnkxhWapm2imBGeStIVXh_VMjp1-TKqIZQwPW9rtueiqIL1lHecdZW6LunZn9dHu9ZAfIAgJxKyc4rCOPDnap36Kup2odH7cOj9uFRx_BUJvmH-Sj-f84fBhfNDA |
| CitedBy_id | crossref_primary_10_1007_s00417_024_06560_4 crossref_primary_10_1016_j_ymeth_2025_02_003 crossref_primary_10_29328_journal_abse_1001024 crossref_primary_10_1016_j_pdpdt_2024_104067 |
| Cites_doi | 10.1097/ICO.0000000000000849 10.1097/01.ico.0000611440.32234.8f 10.1080/02713680802245772 10.1167/iovs.08-1997 10.18637/jss.v050.i12 10.1016/j.ajo.2007.05.028 10.1007/s10792-014-9938-4 10.1007/s00417-014-2851-8 10.1167/iovs.11-7871 10.1167/iovs.08-2805 10.1136/bjophthalmol-2012-302137 10.1016/j.ophtha.2008.02.013 10.1097/ICO.0b013e3180de1d0a 10.1016/j.ophtha.2010.01.039 10.1016/j.exer.2005.08.007 10.1097/ICO.0b013e3182151e0e 10.1007/s004170050118 10.1007/s00417-007-0587-4 10.1097/ICO.0b013e3181e458c5 10.1007/s00417-009-1099-1 10.1097/ICO.0b013e3181d92834 10.1016/j.jcrs.2007.07.012 10.1097/ICO.0000000000002272 10.1097/ICO.0b013e31821c9b44 10.2353/ajpath.2007.070172 10.1001/archopht.126.1.71 10.1097/ICO.0b013e31820cd3f4 10.1136/bjo.2008.144410 10.1016/S0161-620(00)00355-9 10.1136/bjo.2011.204701 10.1590/S1807-59322011000800023 10.1097/ICO.0b013e31823f8d71 10.1001/archophthalmol.2009.18 10.1167/iovs.07-0593 10.1167/iovs.03-1380 10.1002/jps.20178 10.1111/j.1755-3768.2008.01399.x 10.1136/bjo.2005.066225 10.1007/BF00141134 10.1136/bjophthalmol-2011-300856 10.1167/iovs.08-3148 10.1159/000499165 10.1016/j.ophtha.2005.11.019 10.1016/j.burns.2012.07.018 10.1097/ICO.0b013e31818b8be0 10.1007/s00417-009-1170-y 10.1097/ICO.0b013e318158f6ad 10.1007/s00417-006-0466-4 10.1159/000111158 10.1167/iovs.09-4571 10.1152/ajpcell.2001.280.6.C1358 10.1007/s00417-007-0684-4 10.1080/02713680701799101 10.1016/j.ajo.2007.11.003 |
| ContentType | Journal Article |
| Copyright | Copyright © 2023 Peng, He, Yin, Zhou, Zhou and Zhou. Copyright © 2023 Peng, He, Yin, Zhou, Zhou and Zhou. 2023 Peng, He, Yin, Zhou, Zhou and Zhou |
| Copyright_xml | – notice: Copyright © 2023 Peng, He, Yin, Zhou, Zhou and Zhou. – notice: Copyright © 2023 Peng, He, Yin, Zhou, Zhou and Zhou. 2023 Peng, He, Yin, Zhou, Zhou and Zhou |
| DBID | AAYXX CITATION NPM 7X8 5PM DOA |
| DOI | 10.3389/fmed.2023.1210765 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2296-858X |
| ExternalDocumentID | oai_doaj_org_article_b4c1fdc517d34e5da349cb59bfa410ab PMC10324651 37425330 10_3389_fmed_2023_1210765 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: Fundamental Research Funds of the State Key Laboratory of Ophthalmology grantid: 303060202400201119 |
| GroupedDBID | 53G 5VS 9T4 AAFWJ AAYXX ACGFS ACXDI ADBBV ADRAZ AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK GROUPED_DOAJ HYE KQ8 M48 M~E OK1 PGMZT RPM IPNFZ NPM RIG 7X8 5PM |
| ID | FETCH-LOGICAL-c466t-431be7cc43bd49fe1d4b95fa054741500ac82446046ddd21d1b77171c761bf4f3 |
| IEDL.DBID | DOA |
| ISSN | 2296-858X |
| IngestDate | Wed Aug 27 01:26:27 EDT 2025 Thu Aug 21 18:37:06 EDT 2025 Fri Jul 11 00:55:39 EDT 2025 Thu Apr 03 07:03:48 EDT 2025 Thu Apr 24 22:59:11 EDT 2025 Tue Jul 01 00:44:44 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | chemical burns bevacizumab wound healing ocular surface reconstructions corneal neovascularization |
| Language | English |
| License | Copyright © 2023 Peng, He, Yin, Zhou, Zhou and Zhou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c466t-431be7cc43bd49fe1d4b95fa054741500ac82446046ddd21d1b77171c761bf4f3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 These authors have contributed equally to this work Edited by: Enzo Maria Vingolo, Sapienza University of Rome, Italy Reviewed by: Kunpeng Pang, Shandong University, China; Ratnakar Tripathi, University of Missouri, United States |
| OpenAccessLink | https://doaj.org/article/b4c1fdc517d34e5da349cb59bfa410ab |
| PMID | 37425330 |
| PQID | 2839249436 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_b4c1fdc517d34e5da349cb59bfa410ab pubmedcentral_primary_oai_pubmedcentral_nih_gov_10324651 proquest_miscellaneous_2839249436 pubmed_primary_37425330 crossref_citationtrail_10_3389_fmed_2023_1210765 crossref_primary_10_3389_fmed_2023_1210765 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2023-06-22 |
| PublicationDateYYYYMMDD | 2023-06-22 |
| PublicationDate_xml | – month: 06 year: 2023 text: 2023-06-22 day: 22 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland |
| PublicationTitle | Frontiers in medicine |
| PublicationTitleAlternate | Front Med (Lausanne) |
| PublicationYear | 2023 |
| Publisher | Frontiers Media S.A |
| Publisher_xml | – name: Frontiers Media S.A |
| References | Sarchahi (ref41) 2008; 40 Papathanassiou (ref19) 2008; 145 You (ref9) 2009; 87 Dan (ref42) 2008; 33 Cursiefen (ref38) 2012; 96 Jeong (ref47) 2011; 30 Eiger-Moscovich (ref14) 2019; 62 Huang (ref39) 2020; 39 Yoeruek (ref52) 2007; 26 Lazic (ref45) 2007; 245 Kim (ref49) 2008; 115 Dekaris (ref15) 2015; 253 Pillai (ref4) 2000; 41 Chu (ref8) 2011; 30 Nirankari (ref3) 1992; 90 Lobo (ref35) 2004; 93 Amrite (ref33) 2008; 49 Bachmann (ref1) 2010; 117 Uy (ref10) 2008; 27 Raviola (ref34) 1983; 24 Bahar (ref11) 2008; 33 Mello (ref53) 2011; 66 Erdurmus (ref31) 2007; 245 Kim (ref54) 2009; 50 Yoon (ref5) 2007; 144 Bachmann (ref25) 2008; 126 Avery (ref44) 2006; 113 Carrasco (ref7) 2008; 27 Frank Konietschke (ref16) 2012; 50 Fasciani (ref27) 2015; 35 Nakao (ref2) 2007; 171 Enkvetchakul (ref36) 2011; 30 Vassileva (ref20) 2009; 247 Awadein (ref23) 2007; 33 Ferrara (ref43) 2001; 280 Gal-Or (ref13) 2016; 35 Nomoto (ref29) 2009; 50 Robinson (ref32) 2006; 82 Benayoun (ref24) 2012; 31 Lin (ref18) 2010; 51 Brereton (ref30) 2005; 89 Bock (ref50) 2008; 246 Faraj (ref55) 2011; 95 Petsoglou (ref22) 2013; 97 Chung (ref40) 1998; 236 Koenig (ref48) 2009; 247 Chalam (ref51) 2009; 28 Chen (ref21) 2009; 50 Dastjerdi (ref28) 2009; 127 Schmid-Kubista (ref46) 2009; 93 Cursiefen (ref6) 2004; 45 Foroutan (ref26) 2010; 29 Doganay (ref12) 2013; 39 Dastjerdi (ref17) 2011; 52 Lekhanont (ref37) 2012; 31 |
| References_xml | – volume: 35 start-page: 991 year: 2016 ident: ref13 article-title: Efficacy of Subconjunctival Aflibercept versus Bevacizumab for prevention of corneal neovascularization in a rat model publication-title: Cornea doi: 10.1097/ICO.0000000000000849 – volume: 27 start-page: 743 year: 2008 ident: ref7 article-title: Subconjunctival bevacizumab for corneal neovascularization in herpetic stromal keratitis publication-title: Cornea doi: 10.1097/01.ico.0000611440.32234.8f – volume: 33 start-page: 653 year: 2008 ident: ref42 article-title: Inhibitory effect of oral doxycycline on neovascularization in a rat corneal alkali burn model of angiogenesis publication-title: Curr Eye Res doi: 10.1080/02713680802245772 – volume: 50 start-page: 1659 year: 2009 ident: ref21 article-title: Subconjunctival injection of bevacizumab (avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.08-1997 – volume: 50 start-page: 1 year: 2012 ident: ref16 article-title: nparLD: an R software package for the nonparametric analysis of longitudinal data in factorial experiments publication-title: J Stat Softw doi: 10.18637/jss.v050.i12 – volume: 144 start-page: 390 year: 2007 ident: ref5 article-title: Photodynamic therapy with verteporfin for corneal neovascularization publication-title: Am J Ophthalmol doi: 10.1016/j.ajo.2007.05.028 – volume: 35 start-page: 221 year: 2015 ident: ref27 article-title: Subconjunctival and/or intrastromal bevacizumab injections as preconditioning therapy to promote corneal graft survival publication-title: Int Ophthalmol doi: 10.1007/s10792-014-9938-4 – volume: 90 start-page: 595 year: 1992 ident: ref3 article-title: Laser photocoagulation for corneal stromal vascularization publication-title: Trans Am Ophthalmol Soc – volume: 253 start-page: 287 year: 2015 ident: ref15 article-title: Three-year corneal graft survival rate in high-risk cases treated with subconjunctival and topical bevacizumab publication-title: Graefes Arch Clin Exp Ophthalmol doi: 10.1007/s00417-014-2851-8 – volume: 52 start-page: 8718 year: 2011 ident: ref17 article-title: Corneal penetration of topical and subconjunctival bevacizumab publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.11-7871 – volume: 50 start-page: 4653 year: 2009 ident: ref54 article-title: Bevacizumab application delays epithelial healing in rabbit cornea publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.08-2805 – volume: 97 start-page: 28 year: 2013 ident: ref22 article-title: Subconjunctival bevacizumab induces regression of corneal neovascularisation: a pilot randomised placebo-controlled double-masked trial publication-title: Br J Ophthalmol doi: 10.1136/bjophthalmol-2012-302137 – volume: 115 start-page: e33 year: 2008 ident: ref49 article-title: The effect of topical bevacizumab on corneal neovascularization publication-title: Ophthalmology doi: 10.1016/j.ophtha.2008.02.013 – volume: 26 start-page: 977 year: 2007 ident: ref52 article-title: Safety profile of bevacizumab on cultured human corneal cells publication-title: Cornea doi: 10.1097/ICO.0b013e3180de1d0a – volume: 117 start-page: 1300 year: 2010 ident: ref1 article-title: Corneal neovascularization as a risk factor for graft failure and rejection after Keratoplasty an evidence-based Meta-analysis publication-title: Ophthalmology doi: 10.1016/j.ophtha.2010.01.039 – volume: 82 start-page: 479 year: 2006 ident: ref32 article-title: A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide publication-title: Exp Eye Res doi: 10.1016/j.exer.2005.08.007 – volume: 31 start-page: 155 year: 2012 ident: ref37 article-title: Randomized controlled trial of subconjunctival bevacizumab injection in impending recurrent pterygium: a pilot study publication-title: Cornea doi: 10.1097/ICO.0b013e3182151e0e – volume: 236 start-page: 537 year: 1998 ident: ref40 article-title: Effect of 0.1% dexamethasone on epithelial healing in experimental corneal alkali wounds: morphological changes during the repair process publication-title: Graefes Arch Clin Exp Ophthalmol doi: 10.1007/s004170050118 – volume: 245 start-page: 1577 year: 2007 ident: ref31 article-title: Subconjunctival bevacizumab for corneal neovascularization publication-title: Graefes Arch Clin Exp Ophthalmol doi: 10.1007/s00417-007-0587-4 – volume: 30 start-page: 60 year: 2011 ident: ref8 article-title: Subconjunctival injection of bevacizumab in the treatment of corneal neovascularization associated with lipid deposition publication-title: Cornea doi: 10.1097/ICO.0b013e3181e458c5 – volume: 247 start-page: 1375 year: 2009 ident: ref48 article-title: Short-and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization publication-title: Graef Arch Clin Exp doi: 10.1007/s00417-009-1099-1 – volume: 29 start-page: 1268 year: 2010 ident: ref26 article-title: Perilimbal bevacizumab injection for interface neovascularization after deep anterior lamellar keratoplasty publication-title: Cornea doi: 10.1097/ICO.0b013e3181d92834 – volume: 33 start-page: 1991 year: 2007 ident: ref23 article-title: Subconjunctival bevacizumab for vascularized rejected corneal grafts publication-title: J Cataract Refract Surg doi: 10.1016/j.jcrs.2007.07.012 – volume: 39 start-page: 754 year: 2020 ident: ref39 article-title: Early application of Bevacizumab after Sclerocorneal grafting for patients with severe late-stage ocular chemical burns publication-title: Cornea doi: 10.1097/ICO.0000000000002272 – volume: 30 start-page: 1213 year: 2011 ident: ref36 article-title: A randomized controlled trial of intralesional bevacizumab injection on primary pterygium: preliminary results publication-title: Cornea doi: 10.1097/ICO.0b013e31821c9b44 – volume: 171 start-page: 1058 year: 2007 ident: ref2 article-title: Dexamethasone inhibits interleukin-1beta-induced corneal neovascularization: role of nuclear factor-kappaB-activated stromal cells in inflammatory angiogenesis publication-title: Am J Pathol doi: 10.2353/ajpath.2007.070172 – volume: 126 start-page: 71 year: 2008 ident: ref25 article-title: Promotion of graft survival by vascular endothelial growth factor a neutralization after high-risk corneal transplantation publication-title: Arch Ophthalmol doi: 10.1001/archopht.126.1.71 – volume: 30 start-page: 1071 year: 2011 ident: ref47 article-title: Compensatory growth factor and cytokine response in tears after subconjunctival bevacizumab injection publication-title: Cornea doi: 10.1097/ICO.0b013e31820cd3f4 – volume: 93 start-page: 914 year: 2009 ident: ref46 article-title: Systemic bevacizumab (Avastin) therapy for exudative neovascular age-related macular degeneration. The BEAT-AMD-Study publication-title: Brit J Ophthalmol doi: 10.1136/bjo.2008.144410 – volume: 41 start-page: 2148 year: 2000 ident: ref4 article-title: Fine needle diathermy occlusion of corneal vessels publication-title: Invest Ophthalmol Vis Sci doi: 10.1016/S0161-620(00)00355-9 – volume: 96 start-page: 3 year: 2012 ident: ref38 article-title: Consensus statement on indications for anti-angiogenic therapy in the management of corneal diseases associated with neovascularisation: outcome of an expert roundtable publication-title: Br J Ophthalmol doi: 10.1136/bjo.2011.204701 – volume: 66 start-page: 1443 year: 2011 ident: ref53 article-title: The effect of subconjunctival bevacizumab on corneal neovascularization, inflammation and re-epithelization in a rabbit model publication-title: Clinics (São Paulo) doi: 10.1590/S1807-59322011000800023 – volume: 31 start-page: 937 year: 2012 ident: ref24 article-title: Effects of subconjunctival bevacizumab on corneal neovascularization: results of a prospective study publication-title: Cornea doi: 10.1097/ICO.0b013e31823f8d71 – volume: 127 start-page: 381 year: 2009 ident: ref28 article-title: Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study publication-title: Arch Ophthalmol doi: 10.1001/archophthalmol.2009.18 – volume: 49 start-page: 320 year: 2008 ident: ref33 article-title: Modeling of corneal and retinal pharmacokinetics after periocular drug administration publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.07-0593 – volume: 45 start-page: 2666 year: 2004 ident: ref6 article-title: Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.03-1380 – volume: 93 start-page: 2645 year: 2004 ident: ref35 article-title: Antibody pharmacokinetics and pharmacodynamics publication-title: J Pharm Sci doi: 10.1002/jps.20178 – volume: 87 start-page: 653 year: 2009 ident: ref9 article-title: Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization publication-title: Acta Ophthalmol doi: 10.1111/j.1755-3768.2008.01399.x – volume: 89 start-page: 1205 year: 2005 ident: ref30 article-title: Inflfluence of format on in vitro penetration of antibody fragments through porcine cornea publication-title: Br J Ophthalmol doi: 10.1136/bjo.2005.066225 – volume: 24 start-page: 725 year: 1983 ident: ref34 article-title: Conjunctival and episcleral blood vessels are permeable to blood-borne horseradish peroxidase publication-title: Invest Ophthalmol Vis Sci doi: 10.1007/BF00141134 – volume: 95 start-page: 1343 year: 2011 ident: ref55 article-title: Evaluation of corneal neovascularisation publication-title: Br J Ophthalmol doi: 10.1136/bjophthalmol-2011-300856 – volume: 50 start-page: 4807 year: 2009 ident: ref29 article-title: Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.08-3148 – volume: 62 start-page: 116 year: 2019 ident: ref14 article-title: Comparison of Subconjunctival Aflibercept and betamethasone for the treatment of formed corneal neovascularization in a rabbit model publication-title: Ophthalmic Res doi: 10.1159/000499165 – volume: 113 start-page: 363 year: 2006 ident: ref44 article-title: Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration publication-title: Ophthalmology doi: 10.1016/j.ophtha.2005.11.019 – volume: 39 start-page: 326 year: 2013 ident: ref12 article-title: The subconjunctival administration of bevacizumab inhibits corneal neovascularization effectively in the rabbit corneal alkali burn model publication-title: Burns doi: 10.1016/j.burns.2012.07.018 – volume: 28 start-page: 328 year: 2009 ident: ref51 article-title: Evaluation of cytotoxic effects of bevacizumab on human corneal cells publication-title: Cornea doi: 10.1097/ICO.0b013e31818b8be0 – volume: 247 start-page: 1701 year: 2009 ident: ref20 article-title: Avastin use in high risk corneal transplantation publication-title: Graefes Arch Clin Exp Ophthalmol doi: 10.1007/s00417-009-1170-y – volume: 27 start-page: 70 year: 2008 ident: ref10 article-title: Topical bevacizumab and ocular surface neovascularization in patients with stevens-Johnson syndrome publication-title: Cornea doi: 10.1097/ICO.0b013e318158f6ad – volume: 245 start-page: 68 year: 2007 ident: ref45 article-title: Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration publication-title: Graefes Arch Clin Exp Ophthalmol doi: 10.1007/s00417-006-0466-4 – volume: 40 start-page: 41 year: 2008 ident: ref41 article-title: Effects of acetylcysteine and dexamethasone on experimental corneal wounds in rabbits publication-title: Ophthalmic Res doi: 10.1159/000111158 – volume: 51 start-page: 6277 year: 2010 ident: ref18 article-title: The different effects of early and late bevacizumab (Avastin) injection on inhibiting corneal neovascularization and conjunctivalization in rabbit limbal insufficiency publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.09-4571 – volume: 280 start-page: C1358 year: 2001 ident: ref43 article-title: Role of vascular endothelial growth factor in regulation of physiological angiogenesis publication-title: Am J Physiol Cell Physiol doi: 10.1152/ajpcell.2001.280.6.C1358 – volume: 246 start-page: 281 year: 2008 ident: ref50 article-title: Bevacizumab (Avastin) eye drops inhibit corneal neovascularization publication-title: Graefes Arch Clin Exp Ophthalmol doi: 10.1007/s00417-007-0684-4 – volume: 33 start-page: 23 year: 2008 ident: ref11 article-title: Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium publication-title: Curr Eye Res doi: 10.1080/02713680701799101 – volume: 145 start-page: 424 year: 2008 ident: ref19 article-title: Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model publication-title: Am J Ophthalmol doi: 10.1016/j.ajo.2007.11.003 |
| SSID | ssj0001325413 |
| Score | 2.24494 |
| Snippet | To investigate the effect and timing of subconjunctival bevacizumab injection on inhibiting corneal neovascularization (CorNV) in patients after chemical... PurposeTo investigate the effect and timing of subconjunctival bevacizumab injection on inhibiting corneal neovascularization (CorNV) in patients after... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 1210765 |
| SubjectTerms | bevacizumab chemical burns corneal neovascularization Medicine ocular surface reconstructions wound healing |
| SummonAdditionalLinks | – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3LitRAFC3GEcSN-DbjgxJcCZFUqpJKFiIqDoMwbrRhdkU9xx4yae10Bttv8KO9t1Ld2NK4chXImzr3Uuekbs4l5IWrIBBME_Ky1kUugCPnxkqQKr4pQxOstDa6fX6qT2bi41l1dkA27a3SAA57pR32k5otu1c_vq_fQMK_RsUJ8y0g4NHzs-RolQC6vLpGrsPEJDFPTxPbj59cOKghxqe1zf1X7sxO0cR_H_P8u4Dyjxnp-Da5lagkfTthf4cc-P4uuXGaFsvvkV-fx9gNMYwdXfrzqeC1p4tAgUp3a4p01TsK8rMHtgg7t2Wp6d9MatZ0GA0o5guY_bAPWkfn_UUs3or3Mf5K2_nP8VIbOECTR-tA8eMutcmKgAJs_XCfzI4_fHl_kqfmC7kVdb3KgVgYD0gJbpxog2dOmLYKGigekpCi0LYBalCDvnbOlcwxI0EaMitrZoII_AE57Be9f0SorkvvhHReStgICI2mDo32BYe788AyUmwGXdnkTI4NMjoFCgVxUoiTQpxUwikjL7eXfJtsOf518jtEcnsiOmrHHYvluUoJqoywLDhbMem48JXTXLTWVK0JWrBCm4w838SBggzEZRUNwIyDKpFjilbwOiMPp7jYPopLSAXOi4w0OxGz8y67R_r51-jyjU6H2Kj-6H-8_WNyE0cEa9zK8gk5XC1H_xTY1Mo8iznyG9udI6c priority: 102 providerName: Scholars Portal |
| Title | Successful regression of newly formed corneal neovascularization by subconjunctival injection of bevacizumab in patients with chemical burns |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/37425330 https://www.proquest.com/docview/2839249436 https://pubmed.ncbi.nlm.nih.gov/PMC10324651 https://doaj.org/article/b4c1fdc517d34e5da349cb59bfa410ab |
| Volume | 10 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwELXQHhCXihZoQ6EyEiekiDh27OQIiKpCKhdYaW-WP-mulhR1N5Xa38CP7ozjrnZRBRcuiZRPy_MSvxdP3hDy1jcABNvGspamKgVw5NI6BVIltHVso1POJbfPr_JsKr7MmtlWqS_MCRvtgceOe2-FY9G7hinPRWi84aJztulsNIJVxuLbF8a8LTGVvq5wED6Mj9OYoMI6CFNAY9Cao58CiPdmZyBKfv0Pkcw_cyW3Bp_Tp2Qvs0b6YWztPnkU-gPy-DzPiz8jv78NqfBhHJb0KvwYc1t7ehkpsOblDUVmGjwFpdkDMYSNmwzU_BsmtTd0NVgQxwsY6LDk2ZLO-0XK00rXseHauPnt8NNY2EGzHeuK4ndc6rLrAIUI9avnZHr6-funszLXWSidkHJdAoewAYIiuPWii4F5YbsmGmBzyDeqyrgWWIAEKe29r5lnVoEKZE5JZqOI_AWZ9Jd9OCLUyDp4oXxQClYCUNDK2JpQcbg6j6wg1X2na5dNyLEWxlKDGME4aYyTxjjpHKeCvNuc8mt04PjbwR8xkpsD0Tw7bQBI6Qwp_S9IFeTNPQ40PGw4g2IgMMNK10gnRSe4LMjhiIvNrbgC1HNeFaTdQcxOW3b39POLZOiNpoZYk_7l_2j9MXmCPYLpbHX9ikzWV0N4DcRpbU_SMwLLc9HeAX_4HS0 |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Successful+regression+of+newly+formed+corneal+neovascularization+by+subconjunctival+injection+of+bevacizumab+in+patients+with+chemical+burns&rft.jtitle=Frontiers+in+medicine&rft.au=Wen-yan+Peng&rft.au=Li-wen+He&rft.au=Xiao-fang+Yin&rft.au=Bin-Bing+Zhou&rft.date=2023-06-22&rft.pub=Frontiers+Media+S.A&rft.eissn=2296-858X&rft.volume=10&rft_id=info:doi/10.3389%2Ffmed.2023.1210765&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_b4c1fdc517d34e5da349cb59bfa410ab |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2296-858X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2296-858X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2296-858X&client=summon |